血液肿瘤靶向治疗进展  

Advances in the Target Therapy of Hematological Malignancies

作　　者：牛挺[1] 刘霆[1] 

机构地区：[1]四川大学华西医院血液科血液学研究室,成都610041

出　　处：《四川大学学报（医学版）》2014年第4期642-646,542,共5页Journal of Sichuan University(Medical Sciences)

基　　金：卫生部公益项目(No.JH20120437)资助

摘　　要：随着现代生物医学技术如分子生物学、基因组学的快速发展,对血液肿瘤(白血病、淋巴瘤、骨髓瘤)的发病机制有了深入的认识,血液肿瘤的诊断逐渐进入精细化分层诊断,治疗趋势逐渐演化为将新型靶向药物整合到传统的化疗、放疗、造血干细胞移植治疗中。血液肿瘤靶向治疗的重要进展是酪氨酸激酶抑制剂靶向治疗慢性髓细胞白血病,CD20单克隆抗体靶向治疗B细胞淋巴瘤和CD20阳性白血病,FLT3抑制剂靶向治疗FLT3阳性高危急性髓系白血病。本期专题从上述进展反映了血液肿瘤研究的新成果,以及未来血液肿瘤精细化分层诊断和个体化靶向治疗的趋势。With the rapid development of modern bio-medical technology,the pathogenesis of hematological malignancies including leukemia,lymphoma,myeloma has been illustrated with more and more attractive details.The diagnosis of hematological malignancies now becomes more precisely and clarified based on the progress than ever before,and the treatments of hematological malignancies keep the evolution in the way of integrating the novel molecular target drugs with conventional chemotherapy,radiotherapy,hematopoietic stem cell transplantation.The pivotal progress in the target therapy of hematological malignancies includes tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia,CD20monoclonal antibody treatment of B-cell lymphoma and CD20positive leukemia,FLT3inhibitors fo the treatment of FLT3mutation positive high-risk acute myelogenous leukemia.The topics of this issue focus on the advances in this field,which reflects the new achievements in the research of hematological malignancies,and the trends of precise and stratified diagnosis as well as tailored target therapy in the future.

关 键 词：血液肿瘤 靶向治疗 酪氨酸激酶抑制剂 CD20单克隆抗体 FLT3抑制剂 

分 类 号：R733[医药卫生—肿瘤]